Navigation Links
Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
Date:11/20/2008

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates, signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway. Utilising its know-how and fragment-based drug delivery technology platform, Aurigene has generated potent leads against the target. Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones.

"We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work. The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies," said Rolland-Yves Mauvernay, President & Founder of Debiopharm Group.

"Partnering with Debiopharm, a highly focused and successful drug development company, is highly synergistic for Aurigene, a drug discovery biotech. Aurigene has been collaborating with Debiopharm on two other programs for three years now, and the current licensing agreement with Debiopharm serves to reiterate the high quality of science and competence at Aurigene. This further strengthens the relationship between the companies," added CSN Murthy, CEO of Aurigene.

About Debiopharm Group

Debiopharm Grou
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
2. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
3. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
4. Debiopharm and EPFL Establish an Oncology Chair
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Japanese Cancer Association and Debiopharm Honour Japanese Research
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
10. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
11. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... BERNARDSVILLE, N.J., March 16 Protocol Driven Healthcare ... its health risk assessment (HRA), the ConXus(R) ... low literacy and reduces processing costs of paper assessments. ... adult HRA, but joins PDHI,s suite of ConXus ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
... Application Includes Data from a Comparative Trial in ... Inc. announced today that its supplemental New Drug ... Drug Administration (FDA) seeking market approval of Durezol(TM) ... uveitis has been accepted for review. Durezol, ...
Cached Biology Technology:PDHI Launches Short Form of Its ConXus Profile Health Assessment 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 2Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 4Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 5
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... genes that support life in extreme environments, researchers at LSU ... awarded from the National Science Foundation, or NSF, to sequence ... a species known to have evolved extremely high tolerance to ... LSU Associate Professor of Biological Sciences Andrew Whitehead, includes Joe ...
... frog that catches the unsuspecting bug for a tasty snack, ... of ground beetle larvae are able to lure their amphibious ... a report published today in the online journal PLoS ... able to pull off this feat. According to the ...
... four-year, $20 million grant from the U.S. Centers for ... of Public Health (HSPH) researchers to evaluate the impact ... strategies in Botswana. The CDC grant is part of ... initiative that commits $45 million to examine the effectiveness ...
Cached Biology News:Louisiana State University leads collaborative effort to identify genes supporting life in extreme conditions 2Harvard School of Public Health awarded $20 million CDC grant to study HIV prevention in Botswana 2Harvard School of Public Health awarded $20 million CDC grant to study HIV prevention in Botswana 3
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... a glycoprotein. distributed in colon and ... breast, lung and salivary gland tissues. ... MUC1 and MUC2. Epitope: Tandem ... Immunogen: MUC3 tandem repeat peptide ...
... a member of the caudal-related homeobox family, ... both proliferation and differentiation in intestinal epithelial ... triggering cells towards the phenotype of differentiated ... maintenance of the phenotype. Clone CDX2-88 reacts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: